1033739-92-2 Usage
General Description
GNE-490 is a chemical compound that acts as a potent and selective inhibitor of the protein kinase receptor tyrosine-protein kinase erbB-3 (ERBB3). It is being investigated for its potential therapeutic use in the treatment of various types of cancer, including breast, ovarian, and lung cancers. By specifically targeting and inhibiting ERBB3, GNE-490 has shown promising anti-tumor activity in preclinical studies, suggesting that it may be an effective treatment option for cancers that are driven by overexpression or dysregulation of ERBB3 signaling. Additionally, GNE-490 has demonstrated good pharmacokinetic properties and tolerability in animal studies, further supporting its potential as a novel targeted therapy for cancer. Further research and clinical trials are needed to fully evaluate the safety and efficacy of GNE-490 in human patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1033739-92-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,7,3 and 9 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1033739-92:
(9*1)+(8*0)+(7*3)+(6*3)+(5*7)+(4*3)+(3*9)+(2*9)+(1*2)=142
142 % 10 = 2
So 1033739-92-2 is a valid CAS Registry Number.
1033739-92-2Relevant articles and documents
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available Pan-PI3-kinase and dual Pan-PI3-kinase/mTOR inhibitors for the treatment of cancer
Sutherlin, Daniel P.,Sampath, Deepak,Berry, Megan,Castanedo, Georgette,Chang, Zhigang,Chuckowree, Irina,Dotson, Jenna,Folkes, Adrian,Friedman, Lori,Goldsmith, Richard,Heffron, Tim,Lee, Leslie,Lesnick, John,Lewis, Cristina,Mathieu, Simon,Nonomiya, Jim,Olivero, Alan,Pang, Jodie,Prior, Wei Wei,Salphati, Laurent,Sideris, Steve,Tian, Qingping,Tsui, Vickie,Wan, Nan Chi,Wang, Shumei,Wiesmann, Christian,Wong, Susan,Zhu, Bing-Yan
experimental part, p. 1086 - 1097 (2010/08/05)
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural in
